<DOC>
	<DOC>NCT02284425</DOC>
	<brief_summary>This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of REGN1193 in patients with Type 2 Diabetes Mellitus.</brief_summary>
	<brief_title>Study of REGN1193 in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Metformin monotherapy at a dose of ≥1000 mg/day (up to the maximum daily dose of 2550 mg per day) for ≥8 weeks prior to randomization 2. Hemoglobin A1c value of ≥7.0% to ≤10.0% 3. Fasting plasma glucose value ≥130 mg/dL and ≤240 mg/dL 1. Type 1 diabetes mellitus 2. Use of insulin or oral or injectable antihyperglycemic medications during the 8 weeks prior to randomization 3. A severe hypoglycemic event in the 6 months prior to randomization Note: The eligibility criteria listed above is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial therefore not all inclusion/ exclusion criteria are listed.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>